When I heard about the Globus Medical NuVasive merger 2023, my first thought wasn't "great, more options." It was "here we go again."
I manage purchasing for a 120-bed surgical hospital. It's not a huge academic medical center, but we still place somewhere around $4 million in medical device orders a year, and a meaningful chunk of that is spine implants. When I took over purchasing in 2020, I thought the hardest part would be negotiating prices. It wasn't. The hardest part has been understanding what I'm actually buying.
The immediate problem is obvious: the merger changed the landscape. Which products are still supported? Whose training programs are still running? Do I call the NuVasive rep or the Globus Medical rep? But if you stop at those questions, you'll miss the deeper issues that actually determine whether your investment works.
Surface problem: I compared products like I was buying a hospital bed
Let me start with a confession. When I first evaluated spinal implant vendors, I treated the product like a hospital bed. Weight capacity, dimensions, price, lead time—done. A hospital bed is a fairly straightforward purchase: frame, mattress, rails, controls, maybe a few accessories. You can compare spec sheets and make a reasonable decision.
Spine is different. A product code like ALIF, TLIF, XLIF, or ACDF is not a single item. It's a technique, an approach, a set of instruments, and a workflow. When a surgeon asks me for a NuVasive spine system, they're also asking for the retractors, the implants, the navigation compatibility, and the clinical expertise to use them. I can't put that on a spreadsheet.
One way I explain it to new administrators: if you buy a hospital bed, the bed arrives, you plug it in, and the staff knows how to use it by the end of the day. If you buy a spine platform, the implants may be in the box, but the technique has to be in the surgeon's hands. The instrumentation, the training, and the intraoperative support are part of the product.
Deeper issue: You're buying a workflow, not an implant
The real reason my early evaluations failed is that I didn't understand the clinical workflow. That sounds obvious in hindsight, but it took me a while to get there.
Compare that to a cardiac stent. A cardiac stent has specific clinical characteristics—radial strength, drug coating, delivery profile—but at some level, it's still a component that fits into a well-defined procedure. I can look up its FDA clearance and measure it against the hospital's clinical protocols.
Spinal surgery is more like asking "how does mammography work" before buying imaging equipment. You can't evaluate the machine without understanding compression, positioning, and image chain. Similarly, you can't evaluate a spine platform without understanding the surgical technique, patient selection, and the surgeon's training needs.
That's why I now start with the NuVasive official website when I research the company's current portfolio. According to nuvasive.com, the company's focus is minimally invasive spinal surgery systems and clinical services—which is exactly the kind of education and support a surgeon needs before adopting a new technique. But the official website is still marketing. It tells me where they want to lead me; it doesn't tell me what will happen in my OR on a Tuesday afternoon.
Deeper issue: The merger is about platform, not just market share
The Globus Medical NuVasive merger 2023 is often described as combining two spine companies. According to Globus Medical's September 2023 press release, the transaction brought together two musculoskeletal-focused companies with complementary product portfolios. For a buyer, that phrase means two things: possible consolidation and possible confusion.
The combined company kept the Globus Medical name, but NuVasive's products are still a major part of the portfolio. That means I need to know whether a specific NuVasive system has a continuing roadmap or is being treated as a legacy product. I don't take a sales rep's word for it. I check the official website, ask product managers directly, and when needed, check FDA 510(k) records.
The data might say the combined portfolio is broader and the list price is competitive. My gut says mergers create gaps in local coverage. In 2021, I went with a lower-priced vendor because every spreadsheet said they were 12% cheaper. My gut said the local support would be thin. My gut was right—their clinical specialist left two months later and was never replaced. That experience made me biased against any vendor that can't name the three people who will actually show up in our OR.
The hidden cost of getting this wrong
The most frustrating part of evaluating spine vendors is that the cost doesn't show up on the invoice. The implant price is visible. The hidden cost is the surgeon's time, the training, the case coverage, and the delay when something doesn't fit.
At our hospital, we estimate OR time at roughly $60 a minute in opportunity cost. That's not a published number—it's our internal estimate, and it's directionally correct. If a vendor's clinical support is weak and a case runs 30 minutes longer, that's $1,800. Multiply that across a few hundred cases, and the "cheaper" implant is not cheaper.
In our 2024 vendor consolidation project, I realized that the number of vendors wasn't the problem—the number of training hours was. We had three different spine platforms and two different clinical support teams. Consolidating to one platform simplified scheduling and inventory, but only because we verified the merged product roadmap first.
I still kick myself for not asking enough about surgeon training before a different device switch. If I'd asked "Who trains my surgeons, and for how long?" instead of "What's the discount?", I would have saved myself a headache. The vendor promised "full support" and delivered one day of training. Our surgeons were not ready. That was on me.
What I'd do differently: a buyer's checklist
If you're going through this right now, keep the solution simple. Don't try to become a spine surgeon. Instead, verify a few practical things.
- Use the NuVasive official website as a source, not a substitute. Look for current product lines, surgical technique education, and clinical service descriptions. Then ask the company to confirm what's current in writing.
- Ask about the Globus Medical merger in plain terms. Ask, "Which NuVasive products are continuing, which are mature, and which are being consolidated?" A vague answer is a red flag.
- Ask for names. I need the clinical specialists, territory manager, and training coordinator. Not titles—names. If a company won't tell me who covers our region, I assume the coverage is thin.
- Ask for an observation case. Before committing, see the system used in surgery. This matters more than any spec sheet.
- Do not accept the "your order is too small" treatment. I've placed trial orders worth five figures and received less support than I did for a $3,000 instrument. That doesn't work for me. Today's small order can become tomorrow's standard platform.
One final thing: don't let a merger push you into a rushed decision. The market will still be there next quarter. I'd rather take an extra month to verify training and support than sign a contract based on a name that's going to be discontinued. The Globus Medical NuVasive merger 2023 made the vendor landscape bigger, but it also made due diligence more important. Small hospital, large hospital—every hospital deserves a vendor that answers the phone.
